Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. reduced its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 93.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,099 shares of the company's stock after selling 174,189 shares during the quarter. D. E. Shaw & Co. Inc.'s holdings in Keros Therapeutics were worth $192,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of KROS. MetLife Investment Management LLC raised its stake in shares of Keros Therapeutics by 6.0% during the 4th quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock worth $286,000 after buying an additional 1,027 shares during the last quarter. Handelsbanken Fonder AB raised its position in Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after acquiring an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after purchasing an additional 1,372 shares in the last quarter. Virtus ETF Advisers LLC grew its position in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after purchasing an additional 1,998 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Keros Therapeutics by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock valued at $1,549,000 after purchasing an additional 2,462 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

Keros Therapeutics stock traded up $0.25 during midday trading on Friday, hitting $14.27. 480,221 shares of the company were exchanged, compared to its average volume of 845,999. The company's fifty day moving average price is $12.94 and its 200-day moving average price is $20.07. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The company has a market cap of $579.58 million, a PE ratio of -2.74 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same period in the prior year, the business posted ($1.21) EPS. On average, analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 20.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on KROS. Wells Fargo & Company reduced their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. Truist Financial decreased their price objective on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Wedbush reiterated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Friday. Scotiabank lowered their price target on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a report on Monday, May 12th. Finally, HC Wainwright dropped their price objective on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.